Key facts
- Elegen’s last known valuation is $100.0M.
- It has raised $56.6M across 1 recorded rounds; the latest was Early Stage VC ($33.0M) in May 2024.
- Notable investors include Y Combinator, Andreessen Horowitz, 8VC, National Institutes of Health, In-Q-Tel — 17 tracked in total.
- Elegen has filed 1 Form D with the SEC, most recently May 2024 ($33.0M sold to 28 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Elegen
Funding rounds
1 roundsAbout Elegen
Developer of microfluidics technology designed to disrupt synthetic biology. The company leverages technology for the engineering of entire genomes and the rapid development of DNA synthesizers aimed at accelerating biomedical advances, enabling clients to facilitate DNA sequence testing.
- Sector
- Healthcare
- HQ
- Menlo Park, CA, United States
- Founded
- 2017
- Employees
- 96
- Website
- elegenbio.com/
- Ownership
- Privately Held (backing)
Elegen doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Elegen shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Elegen in its N-PORT filings yet. We sweep new filings monthly.